Abacus Bioscience is developing a new class of immunotherapy that unleashes the power of a novel CD180 platform technology. Our Antigen-Specific Immune Accelerants (ASIA) are POTENT, SPECIFIC and DURABLE, with broad applications across infectious disease and oncology.
| Website | http://www.abacusbioscience.com |
| Revenue | $1 million |
| Employees | 4 (3 on RocketReach) |
| Founded | 2017 |
| Phone | +1 425-780-5613 |
| Industry | Biotechnology Research, Pharmaceuticals, Drug Discovery, Healthcare, Biotechnology |
| Keywords | Protein Engineering, Immunotherapy, Immune Response, Cancer Treatment, Infectious Disease, Drug Development, Biotechnology, Pharmaceutical, Clinical Trials, Therapeutics, Bioscience, Biologics, Cell Therapy, Precision Medicine, Vaccine Development, Molecular Medicine |
| Competitors | Roche, Thermo Fisher Scientific, Agilent Technologies, Illumina, PerkinElmer, Inc., Bio-Rad Laboratories, QIAGEN, Molecular Devices, Biosystems LLC, Genomatix AG +38 more (view full list) |
| SIC | SIC Code 80 Companies, SIC Code 873 Companies, SIC Code 28 Companies, SIC Code 283 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies |
Looking for a particular Abacus Bioscience Inc employee's phone or email?
The Abacus Bioscience Inc annual revenue was $1 million in 2026.
Alan Wahl is the CEO of Abacus Bioscience Inc.
3 people are employed at Abacus Bioscience Inc.
Abacus Bioscience Inc is based in Seattle, Washington.
The NAICS codes for Abacus Bioscience Inc are [32, 325, 3254].
The SIC codes for Abacus Bioscience Inc are [80, 873, 28, 283, 87].